| 01.26.22 | J&J extends long-acting injectable pact; EpiPen rival raises $39M

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Webinar: Formulation Strategies: Moving IV to SQ & Vial to PFS

Wednesday, February 16 | 9am ET / 6am PT / 3pm CET

Improving patient compliance is a goal for many biopharma companies. Learn more about strategies when formulating subcutaneous administration and prefilled syringe presentation in this webinar. Register now.

Today's Rundown

J&J extends long-acting injectable biologic pact after Midatech clears early milestone EpiPen rival raises $39M to fund smaller, longer-lasting product Topical combo based on Pfizer and Novartis drugs advances after clearing early clinical test Novaliq eyes dermatology opportunity, spinning off 3 programs and securing $15M for clinical trials Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med

Featured Story

J&J extends long-acting injectable biologic pact after Midatech clears early milestone

By Nick Paul Taylor

Johnson & Johnson has seen enough in Midatech Pharma to extend its drug delivery partnership. The revised deal positions Midatech to optimize a long-acting injectable formulation of an experimental large molecule in development at J&J.

Survey Report: Bridging the Cell and Gene Therapy Gap Between Manufacture and the Supply Chain

Bringing cell, gene-modified cell and gene therapies successfully through the clinical trial process introduces a level of supply chain risk, complexity and specialized requirements which are not yet fully understood. This infographic focuses on taking a closer look at unique clinical supply challenges and unique needs associated with cell and gene therapies. Download Now.

EpiPen rival raises $39M to fund smaller, longer-lasting product

By Nick Paul Taylor

Investors have bought into Windgap Medical’s plan to disrupt the autoinjector market. Just months after disclosing a $17 million round, Windgap has raised $39 million to fund work on a small, temperature-resilient rival to EpiPen.

Topical combo based on Pfizer and Novartis drugs advances after clearing early clinical test

By Nick Paul Taylor

Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it can tame the molecules by combining them in a topical product—and is pushing ahead after getting an early look at clinical data on the candidate.

Novaliq eyes dermatology opportunity, spinning off 3 programs and securing $15M for clinical trials

By Nick Paul Taylor

Novaliq is spinning off its dermatology candidates. Working with VCs, the biotech has set up Dermaliq Therapeutics and secured $15 million to fund early-phase clinical trials of dermatology candidates based on cutaneous drug delivery technology.

Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med

By Angus Liu

Pfizer’s bid to buttress its presence in a pediatric rare disease has hit a snag, giving competitor Acendis Pharma a longer runway to gather speed with a newly approved treatment.

Article Download: Formulation Strategies When Transitioning From Vial to PFS

Prefilled syringes (PFS) can help cut manufacturing and product costs and offers significant benefits to the physician and patient. Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Download Now.